Dynamics of insulin secretion and the clinical implications for obesity and diabetes

S Seino, T Shibasaki, K Minami - The Journal of clinical …, 2011 - Am Soc Clin Investig
Insulin secretion is a highly dynamic process regulated by various factors including
nutrients, hormones, and neuronal inputs. The dynamics of insulin secretion can be studied …

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

MK Cavaghan, DA Ehrmann… - The Journal of clinical …, 2000 - Am Soc Clin Investig
330 The Journal of Clinical Investigation| August 2000| Volume 106| Number 3 ated with a
failure of adequate β-cell mass expansion in the face of insulin resistance. When the …

Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3)

K Yamagata, N Oda, PJ Kaisaki, S Menzel, H Furuta… - Nature, 1996 - nature.com
THE disease non-insulin-dependent (type 2) diabetes mellitus (NIDDM) is characterized by
abnormally high blood glucose resulting from a relative deficiency of insulin1. It affects about …

EADSG guidelines: insulin therapy in diabetes

B Silver, K Ramaiya, SB Andrew, O Fredrick, S Bajaj… - Diabetes therapy, 2018 - Springer
Executive Summary and Recommendations A diagnosis of diabetes or hyperglycemia
should be confirmed prior to ordering, dispensing, or administering insulin (A). Insulin is the …

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects

LL Kjems, JJ Holst, A Vølund, S Madsbad - Diabetes, 2003 - Am Diabetes Assoc
The intestinally derived hormone glucagon-like peptide 1 (GLP-1)(7-36 amide) has potent
effects on glucose-mediated insulin secretion, insulin gene expression, and β-cell growth …

Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function

Y Li, W Xu, Z Liao, B Yao, X Chen, Z Huang… - Diabetes …, 2004 - Am Diabetes Assoc
OBJECTIVE—To investigate whether long-term optimal glycemic control can be achieved
without medication by transient continuous subcutaneous insulin infusion (CSII) and the …

The Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion versus Impaired Insulin Sensitivity

JE Gerich - Endocrine reviews, 1998 - academic.oup.com
Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion versus Impaired Insulin
Sensitivity | Endocrine Reviews | Oxford Academic Skip to Main Content Advertisement Oxford …

Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus

JE Gerich - Mayo Clinic Proceedings, 2003 - Elsevier
Controlled clinical trials have shown that optimal glycemic control can prevent the
microvascular complications of type 2 diabetes mellitus; considerable epidemiological data …

Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12

MM Byrne, J Sturis, S Menzel, K Yamagata… - Diabetes, 1996 - Am Diabetes Assoc
One form of maturity-onset diabetes of the young (MODY) results from mutations in a gene,
designated MODY3, located on chromosome 12 in band q24. The present study was …

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

EJ Verspohl - Pharmacology & therapeutics, 2009 - Elsevier
Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and
hypoglycaemias. A new perspective is the use of incretin hormones and incretin enhancers …